PI3K (~40%), KRAS (~20%) and PTEN (~5%) mutations underlie activation in Type I tumours, whereas Type II tumours exhibit frequent copy number changes and over-expression of PI3K/AKT pathway components (~46%) [4]. This evidence concerns the gene KRAS and neoplasm.